Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer

Nuclear transporter importin-β1 is emerging as an attractive target by virtue of its prevalence in many cancers. However, the lack of druggable inhibitors restricts its therapeutic proof of concept. In the present work, we optimized a natural importin-β1 inhibitor DD1 to afford an improved analog DD...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia-Luo, Yan, Xue-Long, Huang, Dong, Gan, Lu, Gao, Huahua, Fan, Run-Zhu, Li, Shen, Yuan, Fang-Yu, Zhu, Xinying, Tang, Gui-Hua, Chen, Hong-Wu, Wang, Junjian, Yin, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692375/
https://www.ncbi.nlm.nih.gov/pubmed/38045040
http://dx.doi.org/10.1016/j.apsb.2023.07.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692375/
https://www.ncbi.nlm.nih.gov/pubmed/38045040
http://dx.doi.org/10.1016/j.apsb.2023.07.017

Ejemplares similares